Study on the Biological Function of Abemecilib in Inhibiting the Proliferation, Invasion and
Migration of Small Cell Lung Cancer with High c-Myc Expression.
10.3779/j.issn.1009-3419.2023.106.04
- Author:
Jingjing GUO
1
,
2
,
3
,
4
,
5
;
Di MU
1
,
2
,
3
,
4
,
5
;
Wenwen YU
1
,
2
,
3
,
4
,
5
;
Leina SUN
2
,
3
,
4
,
5
,
6
;
Jiali ZHANG
2
,
3
,
4
,
5
,
7
;
Xiubao REN
1
,
2
,
3
,
4
,
5
;
Ying HAN
1
,
2
,
3
,
4
,
5
Author Information
1. Department of Immunology, Tianjin Medical University Cancer Institute and Hospital
2. National Clinical Research Center for Cancer
3. Tianjin Key Laboratory of Cancer Prevention and Therapy
4. Tianjin's Clinical Research Center for Cancer
5. Tianjin Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China.
6. Department of Pathology, Tianjin Medical University Cancer Institute and Hospital
7. Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital
- Publication Type:Journal Article
- Keywords:
Cyclin-dependent kinases 4 and 6;
Lung neoplasms;
c-Myc
- MeSH:
Humans;
Small Cell Lung Carcinoma;
B7-H1 Antigen;
Sincalide;
Lung Neoplasms;
Neoplasm Recurrence, Local;
Transcription Factors;
Adaptor Proteins, Signal Transducing;
Cell Proliferation
- From:
Chinese Journal of Lung Cancer
2023;26(2):105-112
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Small cell lung cancer (SCLC) with high c-Myc expression is prone to relapse and metastasis, leading to extremely low survival rate. Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor Abemaciclib plays a key role in the treatment of tumors, but the effects and mechanisms on SCLC remain unclear. This study was to analyze the effect and molecular mechanism of Abemaciclib in inhibiting proliferation, migration and invasion of SCLC with high c-Myc expression, with a view to expanding a new direction for reducing the recurrence and metastasis.
METHODS:Proteins interacting with CDK4/6 were predicted using the STRING database. The expressions of CDK4/6 and c-Myc in 31 cases of SCLC cancer tissues and paired adjacent normal tissues were analyzed by immunohistochemistry. The effects of Abemaciclib on the proliferation, invasion and migration of SCLC were detected by CCK-8, colony formation assay, Transwell and migration assay. Western blot was used to detect the expressions of CDK4/6 and related transcription factors. Flow cytometry was used to analyze the effects of Abemaciclib on the cell cycle and checkpoint of SCLC.
RESULTS:The expression of CDK4/6 was associated with c-Myc by STRING protein interaction network. c-Myc can directly modalize achaete-scute complex homolog 1 (ASCL1), neuronal differentiation 1 (NEUROD1) and Yes-associated protein 1 (YAP1). Moreover, CDK4 and c-Myc regulate the expression of programmed cell death ligand 1 (PD-L1). Immunohistochemistry showed that the expressions of CDK4/6 and c-Myc in cancer tissues were higher than those in adjacent tissues(P<0.0001). CCK-8, colony formation assay, Transwell and migration assay verified that Abemaciclib could effectively inhibit the proliferation, invasion and migration of SBC-2 and H446OE(P<0.0001). Western blot analysis further showed that Abemaciclib not only inhibited CDK4 (P<0.05) and CDK6 (P<0.05), but also affected c-Myc (P<0.05), ASCL1 (P<0.05), NEUROD1 (P<0.05) and YAP1 (P<0.05), which are related to SCLC invasion and metastasis. Flow cytometry showed that Abemaciclib not only inhibited the cell cycle progression of SCLC cells (P<0.0001), but also significantly increased PD-L1 expression on SBC-2 (P<0.01) and H446OE (P<0.001).
CONCLUSIONS:Abemaciclib significantly inhibits the proliferation, invasion, migration and cell cycle progression of SCLC by inhibiting the expressions of CDK4/6, c-Myc, ASCL1, YAP1 and NEUROD1. Abemaciclib can also increase the expression of PD-L1 in SCLC.
